BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31546041)

  • 21. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
    Hasegawa S; Kondo N; Matsumoto S; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Kamikonya N; Tsujimura T; Nakano T
    Semin Thorac Cardiovasc Surg; 2019; 31(2):301-309. PubMed ID: 30639549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.
    Bertoglio P; Waller DA
    Expert Rev Respir Med; 2016 Jun; 10(6):663-72. PubMed ID: 27015594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
    Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
    Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.
    Rice D; Rusch V; Pass H; Asamura H; Nakano T; Edwards J; Giroux DJ; Hasegawa S; Kernstine KH; Waller D; Rami-Porta R;
    J Thorac Oncol; 2011 Aug; 6(8):1304-12. PubMed ID: 21847060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
    Nakas A; Waller D
    Eur J Cardiothorac Surg; 2014 Sep; 46(3):380-5; discussion 385. PubMed ID: 24482386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
    Hountis P; Chounti M; Matthaios D; Romanidis K; Moraitis S
    J BUON; 2015; 20(2):376-80. PubMed ID: 26011325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
    Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
    Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
    Marulli G; Faccioli E; Bellini A; Mammana M; Rea F
    Expert Rev Respir Med; 2017 Aug; 11(8):649-660. PubMed ID: 28580813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extrapleural pneumonectomies for pleural mesothelioma.
    Faccioli E; Bellini A; Mammana M; Monaci N; Schiavon M; Rea F
    Expert Rev Respir Med; 2020 Jan; 14(1):67-79. PubMed ID: 31674841
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical indications and results after chest wall resection for recurrent mesothelioma.
    Burt BM; Ali SO; DaSilva MC; Yeap BY; Richards WG; Baldini EH; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1373-9; discussion 1379-80. PubMed ID: 24113019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgery as part of radical treatment for malignant pleural mesothelioma.
    Waller DA; Tenconi S
    Curr Opin Pulm Med; 2017 Jul; 23(4):334-338. PubMed ID: 28590338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
    Cao C; Tian D; Park J; Allan J; Pataky KA; Yan TD
    Lung Cancer; 2014 Feb; 83(2):240-5. PubMed ID: 24360321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
    Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kamohara R; Hatachi G; Nagayasu T
    Ann Thorac Cardiovasc Surg; 2018 Apr; 24(2):81-88. PubMed ID: 29367501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
    Friedberg JS
    Semin Thorac Cardiovasc Surg; 2013; 25(2):125-43. PubMed ID: 24216529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.